USD 293.64
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| MDGL | 7.6 | -12.2 | 0.1 | 36.9 | 2.2 | 29.7 | 329.7 | 249.9 | 221.4 | -7.7 |
| S&P 500 | 1.0 | 3.7 | 2.2 | 2.3 | 8.9 | 23.9 | 32.3 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | MDGL |
| name | Madrigal Pharmaceuticals, Inc. |
| price | 293.64 |
| changes percentage | 7.6432 |
| change | 20.85 |
| day low | 270.51 |
| day high | 301.44 |
| year high | 368.29 |
| year low | 168.25 |
| market cap | 6404405856 |
| price avg 50 | 316.891 |
| price avg 200 | 260.94925 |
| exchange | NASDAQ |
| volume | 853056 |
| avg volume | 453888 |
| open | 273.61 |
| previous close | 272.79 |
| eps | -25.04 |
| pe | -11.73 |
| earnings announcement | 2025-02-26T13:30:00.000+0000 |
| shares outstanding | 21810400 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001157601 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -527000 | -467000 | -12.85 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 271823000 | 245441000 | 10.75 |
| operating expenses | 380496000 | 293571000 | 29.61 |
| interest income | 19578000 | 2185000 | 796.02 |
| interest expense | 12712000 | 3964000 | 220.69 |
| ebitda | -379969000 | -293104000 | -29.64 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -380496000 | -293571000 | -29.61 |
| operating income ratio | 0 | 0 | NaN |
| net income | -373630000 | -299314000 | -24.83 |
| net income ratio | 0 | 0 | NaN |
| eps | -19.99 | -17.47 | -14.42 |
Gross Profit: Gross Profit decreased to -1 million in 2023 from 0 million in 2022 representing a change of -12.85%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 380 million in 2023 from 294 million in 2022 representing a change of 29.61%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -19.99 in 2023 from -19.99 in 2022 representing a change of -14.42%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 272 million in 2023 from 245 million in 2022 representing a change of 10.75%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -380 million in 2023 from -293 million in 2022 representing a change of -29.64%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -380 million in 2023 from -294 million in 2022 representing a change of -29.61%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -374 million in 2023 from -299 million in 2022 representing a change of -24.83%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001157601 | |||
| revenue | 62175000 | 14638000 | 324.75 |
| gross profit | 60023000 | 13735000 | 337.01 |
| gross profit ratio | 0.97 | 0.94 | 2.89 |
| research and development expenses | 68742000 | 70824000 | -2.94 |
| operating expenses | 176327000 | 176272000 | 0.03 |
| interest income | 13019000 | 14222000 | -8.46 |
| interest expense | 3679000 | 3656000 | 0.63 |
| ebitda | -102987000 | -148048000 | 30.44 |
| ebitdaratio | -1.66 | -11.09 | 85.06 |
| operating income | -116304000 | -162537000 | 28.44 |
| operating income ratio | -1.87 | -11.1 | 83.15 |
| net income | -106964000 | -151971000 | 29.62 |
| net income ratio | -1.72 | -10.38 | 83.43 |
| eps | -4.92 | -7.1 | 30.70 |
Revenue Growth: revenue increased to 62 million in 2024Q3 from 15 million in 2024Q2 representing a change of 324.75%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 60 million in 2024Q3 from 14 million in 2024Q2 representing a change of 337.01%. This indicates a sales profitability growth, which is a positive sign for the company.
Earnings per Share (EPS): EPS increased to -4.92 in 2024Q3 from -4.92 in 2024Q2 representing a change of 30.7%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 69 million in 2024Q3 from 71 million in 2024Q2 representing a change of -2.94%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 176 million in 2024Q3 from 176 million in 2024Q2 representing a change of 0.03%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -103 million in 2024Q3 from -148 million in 2024Q2 representing a change of 30.44%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -116 million in 2024Q3 from -163 million in 2024Q2 representing a change of 28.44%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -107 million in 2024Q3 from -152 million in 2024Q2 representing a change of 29.62%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001157601 | |||
| total assets | 640547000 | 362572000 | 76.67 |
| total liabilities | 235214000 | 165183000 | 42.40 |
| total equity | 405333000 | 197389000 | 105.35 |
| cash and cash equivalents | 99915000 | 331549000 | -69.86 |
| short term investments | 534216000 | 27225000 | 1862.23 |
| long term investments | 0 | 0 | NaN |
| total current assets | 637281000 | 361369000 | 76.35 |
| total non current assets | 3266000 | 1203000 | 171.49 |
| total current liabilities | 118548000 | 115894000 | 2.29 |
| total non current liabilities | 116666000 | 49289000 | 136.70 |
| common stock | 2000 | 2000 | 0.00 |
| retained earnings | -1336290000 | -962660000 | -38.81 |
| total debt | 117193000 | 49891000 | 134.90 |
Total Assets: Total Assets increased to 641 million in 2023 from 363 million in 2022 representing a change of 76.67%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 405 million in 2023 from 197 million in 2022 representing a change of 105.35%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 534 million in 2023 from 27 million in 2022 representing a change of 1862.23%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 637 million in 2023 from 361 million in 2022 representing a change of 76.35%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 235 million in 2023 from 165 million in 2022 representing a change of 42.4%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 100 million in 2023 from 332 million in 2022 representing a change of -69.86%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 119 million in 2023 from 116 million in 2022 representing a change of 2.29%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,336 million in 2023 from -963 million in 2022 representing a change of -38.81%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 117 million in 2023 from 50 million in 2022 representing a change of 134.9%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001157601 | |||
| total assets | 1073265000 | 1099789000 | -2.41 |
| total liabilities | 296110000 | 242669000 | 22.02 |
| total equity | 777155000 | 857120000 | -9.33 |
| cash and cash equivalents | 232684000 | 499597000 | -53.43 |
| short term investments | 765943000 | 563197000 | 36.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 1063666000 | 1091728000 | -2.57 |
| total non current assets | 9599000 | 8060999 | 19.08 |
| total current liabilities | 177847000 | 125162000 | 42.09 |
| total non current liabilities | 118263000 | 117507000 | 0.64 |
| common stock | 2000 | 2000 | 0.00 |
| retained earnings | -1742766000 | -1635802000 | -6.54 |
| total debt | 119141000 | 118064000 | 0.91 |
Total Assets: Total Assets decreased to 1,073 million in 2024Q3 from 1,100 million in 2024Q2 representing a change of -2.41%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 296 million in 2024Q3 from 243 million in 2024Q2 representing a change of 22.02%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 777 million in 2024Q3 from 857 million in 2024Q2 representing a change of -9.33%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 233 million in 2024Q3 from 500 million in 2024Q2 representing a change of -53.43%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 1,064 million in 2024Q3 from 1,092 million in 2024Q2 representing a change of -2.57%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 178 million in 2024Q3 from 125 million in 2024Q2 representing a change of 42.09%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,743 million in 2024Q3 from -1,636 million in 2024Q2 representing a change of -6.54%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 119 million in 2024Q3 from 118 million in 2024Q2 representing a change of 0.91%. This indicates an increase in overall debt burden.
Short Term Investments: Short Term Investments increased to 766 million in 2024Q3 from 563 million in 2024Q2 representing a change of 36.0%. This indicates an increase in short-term investment holdings.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001157601 | |||
| net change in cash | -231634000 | 295280000 | -178.45 |
| operating cash flow | -324230000 | -224857000 | -44.19 |
| free cash flow | -325709000 | -225074000 | -44.71 |
| capital expenditure | -1479000 | -217000 | -581.57 |
| depreciation and amortization | 527000 | 467000 | 12.85 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 49735000 | 31625000 | 57.26 |
| accounts payables | 4210000 | 2451000 | 71.77 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -3000 | 100.00 |
| investments in property plant and equipment | -1479000 | -217000 | -581.57 |
| net cash used for investing activites | -502520000 | 206686000 | -343.13 |
| debt repayment | 65000000 | 50000000 | 30.00 |
| common stock issued | 260187000 | 255382000 | 1.88 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 595116000 | 313451000 | 89.86 |
| cash at end of period | 99915000 | 331549000 | -69.86 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 331549000 | 36269000 | 814.14 |
Net Change in Cash: Net Change in Cash decreased to -232 million in 2023 from 295 million in 2022 representing a change of -178.45%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -324 million in 2023 from -225 million in 2022 representing a change of -44.19%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -326 million in 2023 from -225 million in 2022 representing a change of -44.71%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 50 million in 2023 from 32 million in 2022 representing a change of 57.26%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 4 million in 2023 from 2 million in 2022 representing a change of 71.77%. This indicates that the company has increased its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure decreased to -1 million in 2023 from 0 million in 2022 representing a change of -581.57%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001157601 | |||
| operating cash flow | -66984000 | -134945000 | 50.36 |
| free cash flow | -67763000 | -140076000 | 51.62 |
| capital expenditure | -779000 | -5131000 | 84.82 |
| depreciation and amortization | 298000 | 267000 | 11.61 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 17898000 | 24404000 | -26.66 |
| accounts receivables | -23564000 | -6899000 | -241.56 |
| accounts payables | 36972000 | -7534000 | 590.74 |
| inventory | -1643000 | -6218000 | 73.58 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -779000 | -5131000 | 84.82 |
| net cash used for investing activites | -202391000 | -122098000 | -65.76 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 7462000 | 85949000 | -91.32 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 7462000 | 134122999 | -94.44 |
| net change in cash | -261913000 | -122920000 | -113.08 |
| cash at end of period | 237684000 | 499597000 | -52.42 |
| cash at beginning of period | 499597000 | 622517000 | -19.75 |
Net Change in Cash: Net Change in Cash decreased to -262 million in 2024Q3 from -123 million in 2024Q2 representing a change of -113.08%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to -1 million in 2024Q3 from -5 million in 2024Q2 representing a change of 84.82%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 37 million in 2024Q3 from 8 million in 2024Q2 representing a change of 590.74%. This indicates that the company has increased its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow increased to -67 million in 2024Q3 from -135 million in 2024Q2 representing a change of 50.36%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -68 million in 2024Q3 from -140 million in 2024Q2 representing a change of 51.62%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 18 million in 2024Q3 from 24 million in 2024Q2 representing a change of -26.66%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -24 million in 2024Q3 from -7 million in 2024Q2 representing a change of -241.56%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -19.99 | -17.47 | -14.47 |
| operating cash flow per share | -17.35 | -13.12 | -32.23 |
| free cash flow per share | -17.43 | -13.13 | -32.70 |
| cash per share | 33.93 | 20.94 | 62.08 |
| book value per share | 21.69 | 11.52 | 88.31 |
| tangible book value per share | 21.69 | 11.52 | 88.31 |
| shareholders equity per share | 21.69 | 11.52 | 88.31 |
| interest debt per share | 6.95 | 3.14 | 121.20 |
| market cap | 4323977148.12 | 4974072590.25 | -13.07 |
| enterprise value | 4341255148.12 | 4692414590.25 | -7.48 |
| pe ratio | -11.57 | -16.62 | 30.36 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -13.34 | -22.12 | 39.71 |
| pfcf ratio | -13.28 | -22.1 | 39.93 |
| pb ratio | 10.67 | 25.2 | -57.67 |
| ptb ratio | 10.67 | 25.2 | -57.67 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -11.43 | -16.01 | 28.63 |
| ev to operating cash flow | -13.39 | -20.87 | 35.84 |
| ev to free cash flow | -13.33 | -20.85 | 36.07 |
| earnings yield | -0.09 | -0.06 | -43.60 |
| free cash flow yield | -0.08 | -0.05 | -66.47 |
| debt to equity | 0.29 | 0.25 | 14.39 |
| debt to assets | 0.18 | 0.14 | 32.96 |
| net debt to ebitda | -0.05 | 0.96 | -104.73 |
| current ratio | 5.38 | 3.12 | 72.40 |
| interest coverage | -29.93 | -74.06 | 59.58 |
| income quality | 0.87 | 0.76 | 13.98 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | -372.67 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 2.81 | 0.46 | 503.97 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 98.78 | 67.28 | 46.82 |
| roic | -0.73 | -1.2 | 39.48 |
| return on tangible assets | -0.58 | -0.83 | 29.34 |
| graham net net | 21.35 | 11.3 | 88.96 |
| working capital | 518733000 | 245475000 | 111.32 |
| tangible asset value | 405333000 | 197389000 | 105.35 |
| net current asset value | 402067000 | 196186000 | 104.94 |
| invested capital | 521999000 | 246678000 | 111.61 |
| average receivables | 0 | 0 | NaN |
| average payables | 25936000 | 22605500 | 14.73 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 19421.19 | 18625.94 | 4.27 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.02 | 0.02 | -4.09 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.92 | -1.52 | 39.21 |
| capex per share | 0.08 | 0.01 | 525.02 |
ROE: Return on Equity (ROE) increased to -0.92 on 2023-12-31 from -1.52 on 2022-12-31, representing a change of 39.21%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 5.38 on 2023-12-31 from 3.12 on 2022-12-31, representing a change of 72.40%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -11.57 on 2023-12-31 from -16.62 on 2022-12-31, representing a change of 30.36%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.29 on 2023-12-31 from 0.25 on 2022-12-31, representing a change of 14.39%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| MDGL | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 2.86 | 0.68 | 318.05 |
| net income per share | -4.92 | -7.1 | 30.73 |
| operating cash flow per share | -3.08 | -6.31 | 51.15 |
| free cash flow per share | -3.12 | -6.54 | 52.39 |
| cash per share | 45.92 | 49.66 | -7.52 |
| book value per share | 35.74 | 40.05 | -10.76 |
| tangible book value per share | 35.52 | 39.82 | -10.80 |
| shareholders equity per share | 35.74 | 40.05 | -10.76 |
| interest debt per share | 5.65 | 5.69 | -0.69 |
| market cap | 4614921052.38 | 5977973054.26 | -22.80 |
| enterprise value | 4501378052.38 | 5596440054.26 | -19.57 |
| pe ratio | -10.79 | -9.83 | -9.68 |
| price to sales ratio | 74.22 | 408.39 | -81.82 |
| pocfratio | -68.9 | -44.3 | -55.52 |
| pfcf ratio | -68.1 | -42.68 | -59.58 |
| pb ratio | 5.94 | 6.97 | -14.86 |
| ptb ratio | 5.94 | 6.97 | -14.86 |
| ev to sales | 72.4 | 382.32 | -81.06 |
| enterprise value over ebitda | -43.71 | -37.8 | -15.63 |
| ev to operating cash flow | -67.2 | -41.47 | -62.04 |
| ev to free cash flow | -66.43 | -39.95 | -66.27 |
| earnings yield | -0.02 | -0.03 | 8.83 |
| free cash flow yield | -0.01 | -0.02 | 37.34 |
| debt to equity | 0.15 | 0.14 | 11.30 |
| debt to assets | 0.11 | 0.11 | 3.41 |
| net debt to ebitda | 1.1 | 2.58 | -57.22 |
| current ratio | 5.98 | 8.72 | -31.43 |
| interest coverage | -31.61 | -44.46 | 28.89 |
| income quality | 0.63 | 0.89 | -29.48 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1.73 | 7.2 | -75.98 |
| research and ddevelopement to revenue | 1.11 | 4.84 | -77.15 |
| intangibles to total assets | 0.0 | 0.0 | 0.57 |
| capex to operating cash flow | -0.01 | -0.04 | 69.41 |
| capex to revenue | 0.01 | 0.35 | -96.43 |
| capex to depreciation | 2.61 | 19.22 | -86.40 |
| stock based compensation to revenue | 0.29 | 1.67 | -82.73 |
| graham number | 62.89 | 79.99 | -21.37 |
| roic | -0.13 | -0.17 | 22.15 |
| return on tangible assets | -0.1 | -0.14 | 27.87 |
| graham net net | 33.56 | 38.73 | -13.35 |
| working capital | 885819000 | 966566000 | -8.35 |
| tangible asset value | 772336000 | 852210000 | -9.37 |
| net current asset value | 767556000 | 849059000 | -9.60 |
| invested capital | 895418000 | 974627000 | -8.13 |
| average receivables | 18681000 | -3568000 | 623.57 |
| average payables | 27480000 | 15261000 | 80.07 |
| average inventory | 7893500 | 3963000 | 99.18 |
| days sales outstanding | 44.1 | 42.42 | 3.96 |
| days payables outstanding | 1922.37 | 896.41 | 114.45 |
| days of inventory on hand | 364.47 | 704.85 | -48.29 |
| receivables turnover | 2.04 | 2.12 | -3.81 |
| payables turnover | 0.05 | 0.1 | -53.37 |
| inventory turnover | 0.25 | 0.13 | 93.39 |
| roe | -0.14 | -0.18 | 22.37 |
| capex per share | 0.04 | 0.24 | -85.06 |
ROE: Return on Equity (ROE) increased to -0.14 on 2024-09-30 Q3 from -0.18 on 2024-06-30 Q2, representing a change of 22.37%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -10.79 on 2024-09-30 Q3 from -9.83 on 2024-06-30 Q2, representing a change of -9.68%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 5.98 on 2024-09-30 Q3 from 8.72 on 2024-06-30 Q2, representing a change of -31.43%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.15 on 2024-09-30 Q3 from 0.14 on 2024-06-30 Q2, representing a change of 11.30%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -0.92 which is lower than current price 293.64, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-19 09:30:00
Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales, driven by Medicare coverage, low market penetration, and European launch, making MDGL stock a STRONG BUY.
Sentiment: Positive
Publish Date: 2025-01-17 08:28:37
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.
Sentiment: Negative
Publish Date: 2025-01-15 10:46:20
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
Sentiment: Neutral
Publish Date: 2025-01-13 11:20:25
Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday.
Sentiment: Positive
Publish Date: 2025-01-13 06:45:00
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net sales, year-end cash and patients on Rezdiffra.
Sentiment: Positive
Publish Date: 2025-01-09 06:22:17
Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing discussion about a potential buyout, adding another layer of interest for investors, and a potential EU launch in H2'25.
Sentiment: Neutral
Publish Date: 2025-01-03 08:00:00
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal's Investor Relations Site, Events and Presentations.
Sentiment: Positive
Publish Date: 2024-11-23 07:46:00
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment.
Sentiment: Positive
Publish Date: 2024-11-22 10:56:10
Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Sentiment: Positive
Publish Date: 2024-11-18 11:00:45
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sentiment: Neutral
Publish Date: 2024-11-11 08:51:11
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
Sentiment: Positive
Publish Date: 2024-11-10 09:30:00
There's a bright future ahead for this company.
Sentiment: Positive
Publish Date: 2024-11-08 08:21:31
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Sentiment: Positive
Publish Date: 2024-11-07 13:00:41
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sentiment: Neutral
Publish Date: 2024-11-06 08:00:00
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Sentiment: Positive
Publish Date: 2024-11-03 09:00:00
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage.
Sentiment: Positive
Publish Date: 2024-11-01 10:46:12
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Sentiment: Negative
Publish Date: 2024-10-31 09:20:21
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
Sentiment: Positive
Publish Date: 2024-10-30 08:00:00
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego.
Sentiment: Positive
Publish Date: 2024-10-28 03:42:58
Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1.1B cash reserves and strategic execution position Rezdiffra as the market leader in NASH/MASH. Analysts forecast substantial revenue growth and narrowing losses for Madrigal, with expectations of profitability within a few years.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
